SAVAYSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SAVAYSA (SAVAYSA).
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
| Metabolism | Primarily metabolized via CYP3A4 and CYP3A5, with minor contributions from CYP2J2. Also undergoes hydrolysis by carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2). |
| Excretion | Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces. |
| Half-life | Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment). |
| Protein binding | Approximately 55% bound to plasma proteins (mainly albumin), with minimal binding to alpha-1-acid glycoprotein. Binding is reversible and not concentration-dependent over clinical range. |
| Volume of Distribution | Volume of distribution is approximately 107 L (1.3-1.5 L/kg). This indicates moderate tissue distribution, with distribution primarily into extracellular fluid. Vd is larger than blood volume due to some tissue binding. |
| Bioavailability | Oral bioavailability is approximately 62% (range 50-80%). Administration with food does not significantly affect absorption (AUC unchanged, Cmax slightly reduced). No alternative routes are clinically relevant. |
| Onset of Action | After oral administration, peak plasma concentrations occur within 1-2 hours (median Tmax 1-2 hours) with rapid onset of anticoagulant effect (anti-Factor Xa activity correlates with plasma concentration). |
| Duration of Action | Anticoagulant effect persists for approximately 12-24 hours after a single dose, supporting once-daily dosing. At steady state, trough levels maintain some activity; effect diminishes within 24 hours after cessation. |
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
| Dosage form | TABLET |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 30-50 mL/min: 2.5 mg twice daily for atrial fibrillation; CrCl 15-30 mL/min: avoid use; CrCl <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: not recommended; Child-Pugh C: contraindicated. |
| Pediatric use | Safety and efficacy not established; no recommended dosing. |
| Geriatric use | No specific dose adjustment based on age alone; monitor renal function as elderly often have reduced CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SAVAYSA (SAVAYSA).
| Breastfeeding | No data on edoxaban in human milk; however, other factor Xa inhibitors are excreted in milk in small amounts. M/P ratio not known. Given the potential for serious adverse reactions in the breastfed infant (e.g., bleeding), breastfeeding is not recommended during treatment. If used, monitor infant for bruising or bleeding. |
| Teratogenic Risk | SAVAYSA (edoxaban) is a direct factor Xa inhibitor. Pregnancy category: Not assigned separately; edoxaban is not recommended in pregnancy. First trimester: Data insufficient to assess risk; animal studies show no teratogenicity at subclinical exposures. Second and third trimesters: Risk of hemorrhage including placental abruption and postpartum hemorrhage; anticoagulant effects may cause fetal bleeding. Placental transfer occurs based on animal data. No adequate human studies. |
■ FDA Black Box Warning
Premature discontinuation of SAVAYSA increases the risk of thrombotic events. Discontinuation for reasons other than pathological bleeding or completion of therapy should be avoided. An epidural or spinal hematoma may occur in patients treated with anticoagulants who receive neuraxial anesthesia or undergo spinal puncture, resulting in long-term or permanent paralysis.
| Serious Effects |
["Active pathological bleeding","History of serious hypersensitivity reaction to edoxaban","Patients with mechanical heart valves","Moderate to severe mitral stenosis with atrial fibrillation"]
| Precautions | ["Increased risk of hemorrhagic stroke in patients with atrial fibrillation","Patients with prosthetic heart valves should not take SAVAYSA","Increased risk of bleeding in patients with renal impairment","Avoid use in patients with moderate or severe hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of bleeding (epistaxis, gingival bleeding, hematuria, easy bruising). Assess hemoglobin/hematocrit periodically. In pregnancy, if used (e.g., for mechanical heart valves where alternatives are contraindicated), perform fetal ultrasound for growth and evidence of hemorrhage. Monitor maternal coagulation status if hemostatic challenges occur. No routine drug level monitoring required. |
| Fertility Effects | No specific human studies on fertility. In animal studies, edoxaban did not affect male or female fertility at doses up to 600 mg/kg. However, as an anticoagulant, it may impact reproductive outcomes through increased risk of bleeding, especially in early pregnancy. Menstrual bleeding pattern may be altered (heavier or prolonged menses). |